Aspen reported NHEPS up 28% in constant currency, to 801.5c. This was above the trading statement midpoint of 800.9c. Revenue was flat in constant currency, at R34.87bn, with reported revenue down 1%. Growth was driven by Commercial Pharmaceuticals, while Manufacturing benefited from sterile FDF improvements. The dividend increased 10% to 232c.
Click here to read the SENS